Platelet-rich plasma (PRP) for Wrist Injuries

Phase-Based Progress Estimates
Wrist Injuries+2 More
Platelet-rich plasma (PRP) - Procedure
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will study whether Platelet-rich Plasma (PRP), a blood concentrate with high levels of growth factors, can help heal Triangular FibroCartilage Complex (TFCC) injuries.

Eligible Conditions
  • Wrist Injuries
  • PRP

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Pre-injection, 2 weeks, 3 months, 6 months, 12 months

12 months post injection
Disability of the Army Shoulder Hand (DASH)
Month 3
Michigan Hand Outcome Questionnaire (MHOQ
Pain Anxiety Symptom Scale (PASS)
Month 12
Mayo Wrist Score (Mayo)
Single Assessment Numerical Evaluation (SANE)

Trial Safety

Trial Design

2 Treatment Groups

Experimental - PRP injection
1 of 2
control - Saline injection
1 of 2

Experimental Treatment

Non-Treatment Group

42 Total Participants · 2 Treatment Groups

Primary Treatment: Platelet-rich plasma (PRP) · Has Placebo Group · N/A

Experimental - PRP injection
Experimental Group · 1 Intervention: Platelet-rich plasma (PRP) · Intervention Types: Procedure
control - Saline injection
PlaceboComparator Group · 1 Intervention: Platelet-rich plasma (PRP) · Intervention Types: Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet-rich plasma (PRP)
Completed Early Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: pre-injection, 2 weeks, 3 months, 6 months, 12 months

Who is running the clinical trial?

William Beaumont Army Medical CenterLead Sponsor
16 Previous Clinical Trials
2,304 Total Patients Enrolled
John C DunnPrincipal InvestigatorWBAMC Staff Hand Surgeon

Eligibility Criteria

Age Any Age · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.